Humanigen Reports Third Quarter 2022 Financial Results

Short Hills, New Jersey--(Newsfile Corp. - November 14, 2022) - Humanigen, Inc. (Nasdaq: HGEN) (Humanigen), a clinical-stage biopharmaceutical company focused on developing lenzilumab (LENZ®), a first-in

Related Keywords

Jordan , ,Esch Group ,Jersey Newsfile Corp ,Humanigen Inc ,Nasdaq ,Short Hills ,Nine Months Ended September ,Humanigen ,Reports ,Third ,Quarter ,022 ,Financial ,Results ,